Last reviewed · How we verify
Testing the Addition of an Anti-cancer Drug, Elimusertib (BAY 1895344) ATR Inhibitor, to the Chemotherapy Treatment (Gemcitabine) for Advanced Pancreatic and Ovarian Cancer, and Advanced Solid Tumors
This phase I trial identifies the best dose, possible benefits and/or side effects of gemcitabine in combination with elimusertib (BAY 1895344) in treating patients with pancreatic, ovarian, and other solid tumors that have spread to other places in the body (advanced). Gemcitabine is a chemotherapy drug that blocks the cell from making DNA and may kill tumor cells. elimusertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving gemcitabine and elimusertib in combination may shrink or stabilize cancer.
Details
| Lead sponsor | National Cancer Institute (NCI) |
|---|---|
| Phase | PHASE1 |
| Status | ACTIVE_NOT_RECRUITING |
| Enrolment | 14 |
| Start date | Tue Jun 01 2021 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Wed May 20 2026 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Advanced Fallopian Tube Carcinoma
- Advanced Malignant Solid Neoplasm
- Advanced Ovarian Carcinoma
- Advanced Pancreatic Adenocarcinoma
- Advanced Primary Peritoneal Carcinoma
- Fallopian Tube High Grade Serous Adenocarcinoma
- Metastatic Pancreatic Adenocarcinoma
- Ovarian High Grade Serous Adenocarcinoma
- Platinum-Resistant Fallopian Tube Carcinoma
- Platinum-Resistant Ovarian Carcinoma
Interventions
- Biopsy Procedure
- Biospecimen Collection
- Diagnostic Imaging Testing
- Elimusertib
- Gemcitabine
Countries
United States